Showing results (41-50 of 149) with videos related to
Sort By:
Pageof 15
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|January 27, 2009
[Is pelvic irradiation still justified in the treatment of prostate cancer by exclusive radiotherapy?]O Chapet, L Quero, D Azria, et al.Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|November 2, 2013
[Hypofractionated radiotherapy, a standard in breast cancer?]C Bourgier, C Lemanski, O Riou, et al.Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|September 2, 2022
[Stereotactic body radiotherapy of primary liver tumours: Indications and new techniques]K Bordeau, M Michalet, A Keskes, et al.Gynecologie, Obstetrique & Fertilite|June 5, 2004
[Secondary debulking surgery and intraperitoneal chemotherapy in advanced or recurrent epithelial ovarian cancer]N Plaisant, F Quenet, M Fabbro, et al.Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|May 27, 2015
[Radiosensitivity settings in breast cancer]O Lauche, D Azria, O Riou, et al.Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|May 26, 2015
[Which node area should be irradiated after neoadjuvant chemotherapy in breast cancer?]C Lemanski, X Druet, O Riou, et al.Bulletin Du Cancer|November 28, 2008
[The value of chemoradiotherapy in the management of locally advanced pancreatic adenocarcinoma: systematic review]D Azria, C Seblain-El-Guerche, N Girard, et al.Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|August 22, 2009
[Prostate cancer: what role for curative radiotherapy in elderly?]T D Nguyen, D Azria, D Brochon, et al.Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|April 21, 2023
Comprehensive commissioning and quality assurance validation of Ethos™ therapyA Morel, J Prunaretty, D Trauchessec, et al.Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|May 6, 2023
Acceptance, commissioning and quality assurance of the MRIdian®: Site experience and three years follow-upS Valdenaire, O Riou, N Aillères, et al.Pageof 15